Aggregation and control of magneto-responsive entities

Patent metadata

Field	Value
Publication number	US-2018102206-A1
Application number	US-201715711436-A
Country	US
Kind code	A1
Filing date	Sep 21, 2017
Priority date	Jun 13, 2012
Publication date	Apr 12, 2018
Grant date	—

Abstract

Applicants have discovered a novel apparatus and method to aggregate and displace a plurality of magneto-responsive entities (steerable self-propelled entities or SSPEs) in three dimensions using time-multiplexing. The apparatus for controlling aggregation of SSPEs in a body comprises at least three sets of magnetic field sources arranged in three axes for generating a controlled magnetic field and a controller connected to at least one of said magnetic field sources to create a three dimensional convergence point. The method for aggregating the entities can comprise using a first set and a second set of said magnetic field sources to generate opposed magnetic field gradients in each said set to cause aggregation of said magneto-responsive entities in two axes and wherein the controller is configured to reverse a direction of said magnetic field gradient in a third set of magnetic field sources in a third axis according to a first predetermined program.

First claim

1 - 39 . (canceled)

40 . A method of treating a patient using magnetotactic bacteria comprising:
introducing therapeutic agent-carrying magnetotactic bacteria to a patient; inserting in said patient and positioning, at a location in proximity to or at a treatment site, a probe capable of generating a magnetic field, wherein said magnetic field is sufficient to induce a directional torque that influences said magnetotactic bacteria; allowing said magnetotactic bacteria to move to and aggregate at or near said probe; delivering said therapeutic agent, carried by said magnetotactic bacteria, at said treatment site; and removing said probe from said patient.

41 . The method as defined in claim 40 , wherein said treatment site is a site of a tumor.

42 . The method as defined in claim 41 , wherein said probe is inserted in a rectum of said patient to reach said site of said tumor.

43 . The method as defined in claim 41 , wherein said probe is inserted in an opening made in said patient during a surgery.

44 . The method as defined in claim 40 , wherein said magnetotactic bacteria are introduced at said location of insertion of said probe.

45 . The method as defined in claim 44 , wherein said probe comprises an injector configured to introduce said magnetotactic bacteria to said patient, and wherein said introducing said magnetotactic bacteria is performed using said injector of said probe.

46 . The method as defined in claim 40 , further comprising adapting the shape of said probe as a function of properties of said treatment site.

47 . The method as defined in claim 40 , further comprising placing a magnetic field source outside of the body of said patient to generate an additional magnetic field to further direct said magnetotactic bacteria to said treatment site.

48 . The method as defined in claim 47 , wherein said magnetic field source is placed on the surface of skin of said patient in proximity to said treatment site.

Assignees

• Polyvalor Lp

Inventors

• Martel Sylvain
• Felfoul Ouajdi

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6901

  Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title

• A61B34/70

  Manipulators specially adapted for use in surgery · CPC title

• H01F7/064 Primary

  Circuit arrangements for actuating electromagnets (circuit arrangements for obtaining special operating characteristics H01F7/18; driving circuits for electromagnets making use of a switching regulator H01H47/325) · CPC title

• A61K47/69

  the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit · CPC title